Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection

被引:30
作者
Dore, GJ
Thomas, DL
机构
[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Viral Hepatitis program, Darlinghurst, NSW 2010, Australia
[2] St Vincents Hosp, HIV Immunol Infect Dis Clin Serv Unit, Darlinghurst, NSW 2010, Australia
[3] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
关键词
hepatitis C; HIV/HCV coinfection; injection drug users;
D O I
10.1055/s-2005-864779
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Injection drug use is the major mode of hepatitis C virus (HCV) transmission in developed countries. Despite this, relatively few current and recovering injection drug users (IDUs) have received HCV treatment. Studies among individuals with a recent history of injection drug use or those receiving drug dependency treatment have provided evidence that these groups can be successfully treated for chronic HCV infection. These studies have provided the impetus to change guidelines for treatment of current and recovering IDUs, with a move toward individualized HCV treatment assessment and the removal of defined periods of illicit drug use abstinence. Strategies to improve access to HCV treatment for current and recovering IDUs include drug dependency treatment education and training for hepatologists and other HCV treatment physicians, HCV treatment education and training for addiction medicine physicians, development of multidisciplinary clinics, and peer-based eduction and support for individuals considering and receiving HCV treatment.
引用
收藏
页码:18 / 32
页数:15
相关论文
共 107 条
[1]   Therapy of acute hepatitis C [J].
Alberti, A ;
Boccato, S ;
Vario, A ;
Benvegnú, L .
HEPATOLOGY, 2002, 36 (05) :S195-S200
[2]   Treatment of chronic hepatitis C in a state correctional facility [J].
Allen, SA ;
Spaulding, AC ;
Osei, AM ;
Taylor, LE ;
Cabral, AM ;
Rich, JD .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (03) :187-190
[3]   THE NATURAL-HISTORY OF COMMUNITY-ACQUIRED HEPATITIS-C IN THE UNITED-STATES [J].
ALTER, MJ ;
MARGOLIS, HS ;
KRAWCZYNSKI, K ;
JUDSON, FN ;
MARES, A ;
ALEXANDER, WJ ;
HU, PY ;
MILLER, JK ;
GERBER, MA ;
SAMPLINER, RE ;
MEEKS, EL ;
BEACH, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (27) :1899-1905
[4]   Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication [J].
Altice, FL ;
Mezger, JA ;
Hodges, J ;
Bruce, RD ;
Marinovich, A ;
Walton, M ;
Springer, SA ;
Friedland, GH .
CLINICAL INFECTIOUS DISEASES, 2004, 38 :S376-S387
[5]   HIV and hepatitis C coinfection within the CAESAR study [J].
Amin, J ;
Kaye, M ;
Skidmore, S ;
Pillay, D ;
Cooper, DA ;
Dore, GJ .
HIV MEDICINE, 2004, 5 (03) :174-179
[6]  
*ANT BOARD NEW S W, 2004, C C HANG REP ENQ HEP
[7]   Treatment of hepatitis C infection in injection drug users [J].
Backmund, M ;
Meyer, K ;
Von Zielonka, M ;
Eichenlaub, D .
HEPATOLOGY, 2001, 34 (01) :188-193
[8]   Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system [J].
Baillargeon, J ;
Wu, H ;
Kelley, MJ ;
Grady, J ;
Linthicum, L ;
Dunn, K .
PUBLIC HEALTH, 2003, 117 (01) :43-48
[9]   Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy [J].
Benhamou, Y ;
Di Martino, V ;
Bochet, M ;
Colombet, G ;
Thibault, V ;
Liou, A ;
Katlama, C ;
Poynard, T .
HEPATOLOGY, 2001, 34 (02) :283-287
[10]   Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients [J].
Benhamou, Y ;
Bochet, M ;
Di Martino, V ;
Charlotte, F ;
Azria, F ;
Coutellier, A ;
Vidaud, M ;
Bricaire, F ;
Opolon, P ;
Katlama, C ;
Poynard, T .
HEPATOLOGY, 1999, 30 (04) :1054-1058